**DTU Library** 



QA prime-boost vaccination strategy in prevent serotype O FMDV infection using a "single-cycle" alphavirus vector and empty capsid particles

Gullberg, Maria; Lohse, Louise; Bøtner, Anette; McInerney, Gerald; Burman, Alison; Jackson, Terry; Polacek, Charlotta; Belsham, Graham

Publication date: 2016

Document Version
Peer reviewed version

Link back to DTU Orbit

Citation (APA):

Gullberg, M., Lohse, L., Bøtner, A., McInerney, G., Burman, A., Jackson, T., Polacek, C., & Belsham, G. (2016). *QA prime-boost vaccination strategy in prevent serotype O FMDV infection using a "single-cycle" alphavirus vector and empty capsid particles*. Abstract from European Commission for the Control of Foot-and-Mouth Disease 2016, Cascais, Portugal.

# General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

#### A PRIME-BOOST VACCINATION STRATEGY IN CATTLE TO PREVENT SEROTYPE O FMDV INFECTION USING A

# "SINGLE-CYCLE" ALPHAVIRUS VECTOR AND EMPTY CAPSID PARTICLES

Maria Gullberg<sup>1</sup>, Louise Lohse<sup>1</sup>, Anette Bøtner<sup>1</sup>, Gerald M. McInerney<sup>2</sup>, Alison Burman<sup>3</sup>, Terry Jackson<sup>3</sup>, Charlotta

Polacek<sup>1</sup> and Graham J. Belsham<sup>1</sup>

# **Introduction**

Foot-and-mouth disease (FMD) remains one of the most economically important infectious diseases of production animals globally. Vaccination can help to control this disease, however, current vaccines based on chemically inactivated FMDV, are imperfect and there is a need for new, safe and effective vaccines to control FMD. There is no cross protection between the 7 serotypes but serotype O is the most abundant globally.

#### **Material and methods**

The FMDV capsid protein precursor (P1-2A) of strain O1 Manisa has been expressed with the FMDV 3C protease (3Cpro) using a "single cycle" packaged alphavirus self-replicating RNA based on Semliki Forest virus (SFV). Purified O1 Manisa empty capsid particles (ECs) have been prepared using a recombinant vaccinia virus expression system. Cattle have been vaccinated with the SFV-FMDV vectors and boosted subsequently with the ECs and then challenged with serotype O FMDV. The immune response against FMDV achieved by vaccination and infection status following challenge has been determined.

## Results

In cattle vaccinated once with these rSFV-FMDV vectors alone, anti-FMDV antibodies were elicited but the immune response was insufficient to give protection against FMDV challenge. However, the vaccination with these vectors resulted in a much stronger immune response against FMDV post-challenge than in naïve animals. In subsequent experiments, cattle were sequentially vaccinated with the rSFV-FMDV followed by recombinant FMDV empty capsid particles prior to challenge. Animals given a primary vaccination with the rSFV-FMDV vector and then boosted with FMDV empty capsids showed a strong anti-FMDV antibody response prior to challenge. Following challenge with serotype O FMDV, the cattle were protected against disease and no FMDV RNA was detected in their sera.

## **Discussion**

This prime-boost system, using reagents that can be generated outside of high-containment facilities, offers significant advantages to achieve control of FMD by vaccination.

<sup>&</sup>lt;sup>1</sup>DTU National Veterinary Institute, Technical University of Denmark, Lindholm, Kalvehave, Denmark

<sup>&</sup>lt;sup>2</sup>Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

<sup>&</sup>lt;sup>3</sup>The Pirbright Institute, Pirbright, Woking, Surrey, U.K